Zebrafish-Based Drug Discovery and Systems Pharmacology

Patient-Derived Cancer Xenograft Zebrafish Model

Zebrafish-Based Drug Discovery and Precision Pharmacology

次世代ゼブラフィッシュ創薬とPrecision Medicine(精密医療)


》第114号 三重大学 Flash News 


第114号 三重大学Flash Newsに12/27のPLoS ONE論文


A High-Throughput Fluorescence-Based Assay System for Appetite-Regulating Gene and Drug Screening
Yasuhito Shimada,Minoru Hirano, Yuhei Nishimura, Toshio Tanaka


The increasing number of people suffering from metabolic syndrome and obesity is becoming a serious problem not only in developed countries, but also in developing countries. However, there are few agents currently approved for the treatment of obesity. Those that are available are mainly appetite suppressants and gastrointestinal fat blockers. We have developed a simple and rapid method for the measurement of the feeding volume of Danio rerio (zebrafish). This assay can be used to screen appetite suppressants and enhancers. In this study, zebrafish were fed viable paramecia that were fluorescently-labeled, and feeding volume was measured using a 96-well microplate reader. Gene expression analysis of brain-derived neurotrophic factor (bdnf), knockdown of appetite-regulating genes (neuropeptide Y, preproinsulin, melanocortin 4 receptor, agouti related protein, and cannabinoid receptor 1), and the administration of clinical appetite suppressants (fluoxetine, sibutramine, mazindol, phentermine, and rimonabant) revealed the similarity among mechanisms regulating appetite in zebrafish and mammals. In combination with behavioral analysis, we were able to evaluate adverse effects on locomotor activities from gene knockdown and chemical treatments. In conclusion, we have developed an assay that uses zebrafish, which can be applied to high-throughput screening and target gene discovery for appetite suppressants and enhancers.


A High-Throughput Fluorescence-Based Assay System for Appetite-Regulating Gene and Drug Screening


三重大学 第114号Flash News